Immunocore Holdings plc's latest moves, explained simply — so you know why the numbers change.
Straight from SEC filings · updated 6 Aug 2026Confirms company leadership has investor approval to manage the business for another term.
Shows how the company performed in early 2026, helping investors track progress.
Provides official quarterly financial data investors need to evaluate company health.
Summarizes annual performance to help investors understand yearly progress and trends.
Gives investors detailed yearly financial data and business overview required for decisions.
Leadership changes can affect drug development pace and company direction.
Stocky reads Immunocore Holdings plc's official filings with the U.S. Securities and Exchange Commission (SEC) — the 8-K, 10-Q and 10-K reports every public company must file — and summarizes each one in plain English, with a link back to the original document.
Immunocore Holdings plc's most recent tracked filing was a 8-K on 27 May 2026: Shareholders re-elect directors Kaul, Pao, and Peterson at May AGM.
No. These event summaries are educational — generated from public SEC filings to help beginners understand what a company is doing. They are not buy or sell recommendations.
Educational, not financial advice. Company events summarized from public SEC filings.
Data as of 6 Aug 2026.